Metacrine
Biotechnology, 3985 Sorrento Vly BLVD Ste C, San Diego, California, 92121, United States, 11-50 Employees
Phone Number: 85********
Who is METACRINE
Metacrine is a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal (GI) diseases. Our most advanced programs target t...
Read More
-
Headquarters: 3985 Sorrento Vly BLVD Ste C, San Diego, California, 92121, United States
-
Date Founded: 2014
-
Employees: 11-50
-
Revenue: $5 Million to $10 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
Email
Phone
Similar Companies to Metacrine
Aktis Oncology
-
11-50
-
$ 1 Million to 5 Million
Artiva Biotherapeutics
-
51-200
-
$ 10 Million to 25 Million
Aulos Bioscience
-
1-10
-
$ Under 1 Million
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Metacrine
Answer: Metacrine's headquarters are located at 3985 Sorrento Vly BLVD Ste C, San Diego, California, 92121, United States
Answer: Metacrine's phone number is 85********
Answer: Metacrine's official website is https://metacrine.com
Answer: Metacrine's revenue is $5 Million to $10 Million
Answer: Metacrine's SIC: 2834
Answer: Metacrine has 11-50 employees
Answer: Metacrine is in Biotechnology
Answer: Metacrine top competitors include: Aktis Oncology , Artiva Biotherapeutics , Aulos Bioscience
Answer: Metacrine contact info: Phone number: 85******** Website: https://metacrine.com
Answer: Metacrine is a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal (GI) diseases. Our most advanced programs target the farnesoid X receptor (FXR), which is central to modulating liver and GI diseases. FXR agonism has been investigated in large-scale clinical trials and has shown clinically relevant improvements in non-alcoholic steatohepatitis (NASH), a liver disease that affects 17 million people in the U.S. and is characterized by excess liver fat, inflammation and fibrosis. We believe that potency and continuous target engagement are key to optimizing therapeutic benefit with an FXR targeted therapy. Leveraging our extensive chemistry and biology expertise, we have built a proprietary library of over 2,500 FXR compounds, and have selected two oral FXR candidates from a unique chemical scaffold, MET409 and MET642. With our platform, we believe we can develop differentiated FXR agonist therapies for liver and GI diseases.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month